Receive The Newest Study Notifications

--Study Achieves All Primary Endpoints; Company to Set Meeting with FDA Regarding Pivotal Trial Design-- PHILADELPHIA, Dec. 4, 2019 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced positive results from the first human study evaluating insulin...

--Clinical Trial Aims to Confirm Data Showing that Cognizance's EvoScoreDX Protein Biomarker Assay Can Accurately Distinguish Epileptic Seizures from Psychogenic Seizures-- SPRING HOUSE, Pa., Dec. 4, 2019 /PRNewswire/ -- Cognizance Biomarkers, LLC, a wholly-owned...

Top-line results expected in the second half of 2020 Ra Pharmaceuticals, Inc. (RARX) today announced the initiation of dosing in its Phase 2 clinical trial of zilucoplan for the treatment of immune-mediated necrotizing myopathy (IMNM). “IMNM is a chronic, severe, and...

Phase 2a clinical trial for topical cerdulatinib to enroll 30 patients with vitiligo Top-line results anticipated in second half of 2020 BASEL, Switzerland and LONG BEACH, CA, USA I December 03, 2019 I Dermavant Sciences, a dermatology-focused subsidiary of Roivant...

SALT LAKE CITY, Dec. 3, 2019 /PRNewswire/ -- Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, today announced the dosing of the first participant enrolled in the REPAIR-PD study with its lead nanocatalytic therapy, CNM-Au8, for the treatment of...

TEMPE, A.Z. and FARGO, N.D., Dec. 03, 2019 (GLOBE NEWSWIRE) -- Prevention of cancer onset is the ultimate aspiration for animals and humans. Cancer is caused by mutations that are specific to the tumor which continues to mutate -- making it extremely difficult for the...

BRISBANE, Australia, Dec. 3, 2019 /PRNewswire/ -- QBiotics Group Limited (QGL), a life sciences company developing novel anticancer and wound healing pharmaceuticals, today announced that it has dosed its first patient in a Phase I/II clinical trial evaluating the...

Companies to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Cancer Seattle Genetics, Inc. and Astellas Pharma Inc.have announced a clinical collaboration agreement with Merck, known as MSD outside the...

No evidence of cardiotoxicity to date; 40% of 10 patients dosed at ≥120 mg/m² demonstrate efficacy; trial progresses in Europe to 210 mg/m² HOUSTON, Dec. 4, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage...

Baseline-matched Real-World external Control Data with Alzheimer’s Disease Neuroimaging Initiative (ADNI): ANAVEX®2-73 (blarcamesine) Cohort showed a Significantly lower Cognitive Decline Compared to the ADNI Control Cohort at Interim 2-Year (104-Week) Timepoint...

ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, announced the recent achievement of two significant clinical trial milestones, enrollment of 60...

First patient successfully dosed in QBiotics' Phase I/II clinical trial of tigilanol tiglate in patients with Head and Neck Squamous Cell Carcinoma (HNSCC) Tigilanol tiglate is a novel, small molecule that is being tested as a single injection treatment for solid...

Phase 2a clinical trial for topical cerdulatinib to enroll 30 patients with vitiligo Top-line results anticipated in second half of 2020 BASEL, Switzerland and LONG BEACH, Calif., Dec. 03, 2019 (GLOBE NEWSWIRE) -- Dermavant Sciences, a dermatology-focused subsidiary...

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today it has completed patient enrollment in its...

Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (OM), today announced the completion of enrollment in its ongoing double-blind, randomized, placebo-controlled...

TrialScope, in conjunction with EMD Serono, has launched a new clinical trials website. The site is designed to inform the public and healthcare professionals about clinical trials in general and provide details on EMD Serono clinical trials. EMD Serono Clinical...

BOTHELL, Wash., and TOKYO, Dec. 2, 2019 /PRNewswire/ -- Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas"), today announced a clinical collaboration agreement with Merck, known as MSD...

SALT LAKE CITY, Dec. 3, 2019 /PRNewswire/ -- Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, today announced the dosing of the first participant enrolled in the REPAIR-PD study with its lead nanocatalytic therapy, CNM-Au8, for the treatment of...

Biospace's Mark Terry Clinical Trial Review Even with a shortened week due to the U.S. Thanksgiving holiday, there was plenty of clinical trial news and updates. Here’s a look. Genentech, a Roche company, presented positive results from the Phase III IMbrave150...

Enrollment Complete for Phase 2 Trial of AGO13 in Oral Mucositis Oragenics, Inc. (NYSE:OGEN) is currently conducting a Phase 2 clinical trial of its lead development compound AG013 in the prevention of severe oral mucositis (OM). AG013 is an oral mouth rinse composed...